Index to Volume Ten

Index of Issues: January–March 1–52; April–June 53–110; July–September 111–166; October–December 167–224; Supplement to October–December, pp. 225–385.

INDEX OF AUTHORS

A

Adam E, 67
Adler-Storthz K, 67
Albritton WL, 1
Alexander ER, 184
Alfa M, 232
Altman NL, 208
Aral SO, 72, 77, 100
Austin TW, 119

B

Baldetorp B, 363
Ballard RC, 33, 285
Banks JP, 355
Barile MF, 345
Batts DH, 202
Beebe JL, 195
Berg SW, 135
Biddle JW, 53, 56
Blanco JD, 303
Blount JH, 72, 77
Boatman ES, 232
Bos JD, 148
Boyce WT, 184
Brooks GF, 173
Brorson J-E, 327
Brown DA, 173
Brown MB, 247, 294
Brunham RC, 374
Burns M, 180
Bygdeman SM, 366

C

Cassell GH, 247, 294
Castaneda YS, 303
Cates W Jr, 219
Catterall RD, 85
Chandler DKF, 345
Chen KCS, 271
Chowdhury MNH, 45
Christiansen C, 230
Christiansen G, 230
Christiansson A, 240, 371
Clark VL, 7
Cles LD, 123
Cohen RL, 202
Cole B, 374
Conrad GL, 36
Cox DW, 180
Crowley B, 184

D

D'Costa LJ, 1
Darrow WW, 77
Darwish R, 119
Davick P, 374
Davis JK, 247, 294
Davis RO, 294
Draper DL, 173
Dreesman G, 67

E

Edwards T, 180
Eisen R, 43
Embil JA, 62, 114, 307
Embree JE, 307

F

Faber WR, 148
Fall M, 327
Fan P, 141
Fass H, 148
Fast M, 285
Fast MV, 1
Fichtner RR, 72, 77, 100
Fiumara NJ, 43, 53, 126, 144
Fogle JS II, 29
Freischlag J, 153
Freundt EA, 226, 359
Furr PM, 256, 341

G

Gabay EL, 39
Gibbs RS, 303
Grabowski MW, 345
Greaves WL, 53
Guinan ME, 53
Guzick DS, 138

H

Haffner WHJ, 184
Hale J, 318, 374
Hallinan J, 39
Handsfield HH, 191, 198
Hansen E, 230
Harrison HR, 184, 311
Harrison WO, 135
Hashisaki P, 36
Hawkins DA, 256
Hayes L, 130
Hedelin HH, 327
Hesse FE, 123
Hill LH, 114
Holmes KK, 271, 276, 318, 374

I

Izumikawa K, 345

J

James JF, 173
Jansson E, 289
Johnson RE, 100
Jones OG, 72
Jones PG, 202
Judson FN, 24

K

Kampmeier RH, 47, 81, 156, 205
Karasira P, 1
Katta LR, 138
Kaufman R, 67
Keat AC, 341
Kennedy RC, 67
Kerbs S, 135
Kit S, 67
Kiviat N, 276
Kothe FC, 200
Koutsky LA, 374
Kramer M, 180
Kramer MA, 56
Kraus SJ, 53, 56, 180
Krause VW, 307
Kuo C-C, 276

L

Lalonde RG, 130
Lammel CJ, 173
Leinikki P, 289
Lessell S, 126
Lewis M, 184
Lovett MA, 39
Lukehart SA, 198

M

MacDonald SW, 62
Maclean IW, 1
Magalhaes M, 151
Manuel FR, 62
Mardh P-A, 160, 225, 240, 285, 327, 331, 363, 366, 371, 382
Markewich GS, 29
Marriott PA, 294
McBride ME, 111
McCormack WM, 53, 160, 225, 261
Meheus A, 33, 285
Messing M, 56
Miettinen A, 271, 276, 289
Minion C, 247
Moller BR, 160, 225, 281, 285, 327, 359
Mufson MA, 335
Myhre EB, 382

N

Nichols CR, 36
Noble RC, 14, 18, 187
Nsanze H, 1, 285

O

O'Brien SJ, 345
Oriel JD, 263
Ostrow DG, 208

P

Paavonen J, 271, 276, 289
Pareek SS, 45
Parekh MC, 14, 18, 187
Pattison FLM, 119
Pereira LH, 62
Pettersson KSS, 327
Piot P, 1, 33, 285
Potterat JJ, 29
Pratts CI, 29
Pritchard DG, 247

Q

Qavi H, 67

R

Ralph ED, 119
Rathbun KC, 93, 102
Ray RM, 123
Reynolds GH, 72, 77, 100
Rietra PJGM, 148
Risseeuw-Appel IM, 200
Robertson JA, 232
Robson HG, 130
Roddy R, 198
Ronald A, 285
Ronald AR, 1
Rose DL, 256
Rossi PH, 180
Rothenberg R, 24, 216
Running K, 318
Ruparelia H, 114

S

Sanchez PL, 135
Schachter J, 123, 355
Schlater LK, 56
Senikas VM, 130
Shah PP, 130
Silva J Jr, 202
Simonson JM, 345
Smith EA, 119
Soendjojo A, 41
Solomon J, 144
Sottnek FO, 56
Spence MR, 138
St. Clair PJ, 303
Stagno S, 294
Stamm WE, 276, 318, 374
Stein DC, 7
Stephens EB, 345
Stevens CE, 271, 276, 374
Stray-Pedersen B, 167
Sweet RL, 173
Swenson CE, 355

T

Taylor-Robinson D, 256, 341, 345
Thiebaux J, 62
Thomas BJ, 341
Thomas DS, 153
Thompson JE Jr, 153
Thomsen AC, 323
Trkula D, 67
Tully JG, 256, 345

U

Ursi J-P, 285
Ursi JP, 33

V

van Dyck E, 33, 285
Van Eijk RVW, 148
Vinther O, 244

W

Waites KB, 294
Weiner SR, 141
Weinstein L, 184
Wertzberger GG, 36
Westrom L, 363
Wignall FS, 135
Woodhouse DE, 29

Y

Young FE, 7

Z

Zaidi A, 53
Zaidi AA, 72, 77, 100
Zajdowicz TR, 135

INDEX OF SUBJECTS

A

Acquired immune deficiency syndrome, in homosexual man, opportunistic infection in (Jones & others), 202
Acyclovir ointment, in dark-field examination in primary syphilis (Roddy; Lukehart & Handsfield), 198
Africa, genital ulcerations in, *M. hominis* in (Piot & others), 285
American Indian population, pregnancy in, *C. trachomatis* and mycoplasmal infection in (Harrison & others), 184
Amniotic fluid, at 16–20 weeks gestation, *M. hominis* and *U. urealyticum* in, pregnancy outcome in (Cassell & others), 294
Amoxicillin, oral, treponemicidal levels of, in cerebrospinal fluid (Faber & others), 148
Antibody screening test, gonococcal, physician utilization of (Beebe), 195
Antigen, of *Mycoplasma hominis* (Brown & others), 247
Antimicrobial susceptibility testing, of *M. hominis* (Bygdeman & Mårdh), 366
Antimicrobial therapy, of chancroid (Fast & others), 1
Arthritis, *M. hominis* in (Taylor-Robinson & others), 341
Arthritis-dermatitis, gonococcal, popliteal cyst involvement in (Weiner & Fan), 141
Aspergillosis, invasive pulmonary, in homosexual patient with AIDS (Jones & others), 202

B

Black patients, *N. gonorrhoeae* auxotypes and (Nobel & Parekh), 14

C

Cefaclor, *N. gonorrhoeae* susceptibility to (Noble & Parekh), 18
Cefoxitin
  in gonococcal urethritis due to penicillinase-producing *N. gonorrhoeae* (Sanchez & others), 135
  N. gonorrhoeae susceptibility to (Noble & Parekh), 18
  penicillin vs, in uncomplicated gonorrhea (Greaves & others), 53
Central nervous system, in newborns, *M. hominis* infection in (Mårdh), 331
Cerebrospinal fluid, oral amoxicillin and, treponemicidal levels of (Faber & others), 148
Cervicitis, *M. hominis* in (Paavonen & others), 276
Cervix
  C. trachomatis infection with, rosaramicin vs erythromycin stearate in (Robson & others), 130
  sequential specimens from, in isolation of *Chlamydia trachomatis* (Embil & others), 62
Chancroid, antimicrobial therapy of (Fast & others), 1
Chlamydia trachomatis
  cervical infection with, rosaramicin vs erythromycin stearate in (Robson & others), 130
  genital tract infections of, immunity to (Schachter & others), 123
  isolation of, sequential cervical specimens in (Embil & others), 62
  during pregnancy, in American Indian population (Harrison & others), 184
Ciliated epithelia of genital tract, *M. hominis* challenge with (Baldetorp; Mårdh & Weström), 363
Computerized tomographic findings, in meningovascular syphilis (Gabay; Hallinan & Lovett), 39
Cost–benefit analysis (editorial) (Rothenberg), 216
Culture media, for *Mycoplasma hominis* (Tully & others), 256
Cystitis, interstitial, *M. hominis* in (Hedelin & others), 327

D

Dark-field examination, in primary syphilis, acyclovir ointment and (Roddy; Lukehart & Handsfield), 198
Demographic effects on sexually transmitted disease in 1970s (editorial) (Aral & others), 100

E

Endometritis, *M. hominis* in (Paavonen & others), 276
Enzyme immunoassay, for *M. hominis*, in pelvic inflammatory disease (Miettinen & others), 289
Epidemiology, of *M. hominis* (McCormack), 261
Erythema multiforme, recurrent (Fiumara & Solomon), 144
Erythromycin, failure of, in syphilis in pregnancy (Hashisaki & others), 36
Erythromycin stearate, rosaramicin vs, in cervical infection with *C. trachomatis* (Robson & others), 130
Eukaryotic cells, gonococcal attachment to (James & others), 173
Extragenital infection, *M. hominis* in (Myhre & Mårdh), 382

F

Fellatio, gonococcal urethritis due to (Soendjojo), 41
Flocculation screening test, for syphilis, evolution of (Kampmeier), 156

G

Genital tract, *Haemophilus* species isolation from (Messing & others), 56
Genital ulceration, in Swaziland (Meheus & others), 33
Genito-anal-rectal syndrome, as late manifestations of lymphogranuloma inguinale (Kampmeier), 47
Genotypic properties, of *M. hominis* (Barile & others), 345
Gonococcal antibody screening test, physician utilization of (Beebe), 195
Gonococcal attachment to eukaryotic cells (James & others), 173
Gonorrhea
  men with, women contacts of (Potterat & others), 29
  sulfonamide therapy for (Kampmeier), 81
  uncomplicated
    cefoxitin vs penicillin in (Greaves & others), 53
    single-dose moxalactam in (Handsfield), 191
  in United States from 1967–1979 (Zaidi & others), 72
Gonozyme test, preliminary evaluation of (Burns & others), 180

H

Haemophilus parainfluenzae, in urethritis (Chowdhury & Pareek), 45
Haemophilus species, isolation of, from genital tract (Messing & others), 56
Herpes simplex types 1 and 2, sequential genital infections by, restriction nuclease analysis in (Kit & others), 67
Herpes simplex virus infection, recurrent (Fiumara & Solomon), 144
Histoplasmosis, disseminated, in homosexual patient with AIDS (Jones & others), 202
Homosexual man
  AIDS in, histoplasmosis, aspergillosis, and opportunistic infections in (Jones & others), 202
  amebic liver abscess in (Thompson; Freischlag & Thomas), 153
Homosexuality, sexually transmitted diseases and (Ostrow & Altman), 208

I

Immobilizing antibody, for *T. pallidum* (Kampmeier), 205
Immunity, to *C. trachomatis* of genital tract (Schachter & others), 123
Infant, newborn, central nervous system of, *M. hominis* infection in (Mårdh), 331

L

Liver abscess, amebic, in homosexual man (Thompson; Freischlag & Thomas), 153
Lymphogranuloma inguinale, genito-anal-rectal syndrome in (Kampmeier), 47

M

Maternal screening for congenital syphilis, economic evaluation of (Stray-Pedersen), 167
Metronidazole, susceptibility of *T. vaginalis* to (Ralph & others), 119
Monkey animal model, of mycoplasmal infection of urogenital tract (Møller & Freundt), 359
Moxalactam
  N. gonorrhoeae susceptibility to (Noble & Parekh), 18
  single-dose, in uncomplicated gonorrhea (Handsfield), 191
Mycoplasma hominis
  in amniotic fluid at 16–20 weeks gestation, pregnancy outcome and (Cassell & others), 294
  antigens of (Brown & others), 247
  antimicrobial susceptibility testing of (Bygdeman & Mårdh), 366
  in arthritis (Taylor-Robinson & others), 341
  as human pathogen (McCormack; Møller & Mårdh), 160
  biochemistry of (Vinther), 244
  in central nervous infection in newborns (Mårdh), 331
  in cervicitis and endometritis (Paavonen & others), 276
  chemical composition and ultrastructure of (Christiansson & Mårdh), 240
  ciliated epithelia of genital tract and (Baldetorp; Mårdh & Weström), 363
  enzyme immunoassay for, in acute pelvic inflammatory disease (Miettinen & others), 289
  epidemiology of (McCormack), 261
  extragenital infections caused by (Myhre & Mårdh), 382
  in genital ulcerations in Africa (Piot & others), 285
  historical outline and taxonomy for (Freundt), 226
  international symposium on (Mårdh; Møller & McCormack), 225
  interstitial cystitis and (Hedelin & others), 327
  in late pregnancy (Gibbs & others), 303
  monkey model for study of (Møller & Freundt), 359
  morphology of cells and colonies in (Roberston; Alfa & Boatman), 232
  in nongonococcal urethritis and prostatitis (Oriel), 263
  in nonspecific vaginitis (Paavonen & others), 271
  organ culture studies of (Swenson; Banks & Schachter), 355
  other *Mycoplasma* species and, genetic relation between (Christiansen; Hansen & Christiansen), 230
  as placental pathogen (Embree; Krause & Embil), 307
  during pregnancy, in American Indian population (Harrison & others), 184
  in pregnancy, prospective studies in (Harrison), 311
  in respiratory tract (Mufson), 335
  tetracycline resistance of (Christiansson & Mårdh), 240
    coexisting vaginal flora in (Koutsky & others), 374
  tissue cell interactions with, phenotypic and genotypic properties in (Barile & others), 345
  upper genital tract of women and (Møller), 281
  in upper urinary tract (Thomsen), 323
  urogenital tract recovery of, culture media in (Tully & others), 256
  in women with acute urethral syndrome (Stamm & others), 318

N

Neisseria gonorrhoeae
  auxotypes of
    attachment to donor cells, of African, European, Indian descent and (Noble & Parekh), 187
    in black and white patients (Nobel & Parekh), 14
    penicillin G, spectinomycin, tetracycline, cefaclor, cefoxitin, moxalactam and (Noble & Parekh), 18
  inhibition of, pyocin 103 in (Stein; Clark & Young), 7
  isolation of, three culture transport systems in (Spence; Guzick & Katta), 138
  penicillinase-producing, in gonococcal urethritis, cefoxitin in (Sanchez & others), 135
  storage of, quantitative disk method for (McBride), 111

O

Organ culture studies, of *M. hominis* (Swenson; Banks & Schachter), 355

P

Pelvic inflammatory disease, *M. hominis* in, enzyme immunoassay for (Miettinen & others), 289
Penicillin, cefoxitin vs, in uncomplicated gonorrhea (Greaves & others), 53
Penicillin G, *N. gonorrhoeae* auxotype sensitivity to (Noble & Parekh), 18
Penile ring, titivating (Fiumara & Eisen), 43
Phenotypic properties, of *M. hominis* (Barile & others), 345
Placenta, *M. hominis* as pathogen of (Embree; Krause & Embil), 307
Popliteal cyst involvement, in gonococcal arthritis–dermatitis syndrome (Weiner & Fan), 141
Pregnancy
  C. trachomatis and mycoplasmal infection during, in American Indian population (Harrison & others), 184
  late, *M. hominis* infection in (Gibbs & others), 303
  M. hominis and *U. urealyticum* infection in, at 16–20 weeks gestation (Cassell & others), 294
  M. hominis infection in, prospective studies of (Harrison), 311
  syphilis in, erythromycin failure in (Hashisaki & others), 36
Prostatitis, nongonococcal, genital mycoplasmas in (Oriel), 263
Pyocin 103, inhibition of *Neisseria gonorrhoeae* by (Stein; Clark & Young), 7

Q

Quantitative disk method, for storage of *N. gonorrheae* (McBride), 111

R

Respiratory tract, *M. hominis* infection in (Mufson), 335
Restriction nuclease analysis, in sequential genital infection, by herpes simplex virus types 1 and 2 (Kit & others), 67
Rosaramicin, erythromycin stearate vs, in cervical infection with *C. trachomatis* (Robson & others), 130

S

Sexually transmitted disease
  demographic effects of, in 1970s (editorial) (Aral & others), 100
  homosexuality and (Ostrow & Altman), 208

Specialty, emergence of (Catterall), 85
Spectinomycin, *N. gonorrhoeae* susceptibility to (Noble & Parekh), 18
Stigmata, of late congenital syphilis (Fiumara & Lessell), 126
Sulfonamide, for gonorrhea (Kampmeier), 81
Swaziland, genital ulcerations in, etiology of (Meheus & others), 33
Syphilis
  congenital (Rathbun), 93
    economic evaluation of maternal screening for (Stray-Pedersen), 167
    improved surveillance, diagnosis, treatment of (editorial) (Rathbun), 102
    stigmata of (Fiumara & Lessell), 126
  flocculation screening test for, evolution of (Kampmeier), 156
  meningovascular, computerized tomographic findings in (Gabay; Hallinan & Lovett), 39
  in pregnancy, erythromycin failure in (Hashisaki & others), 36
  primary, dark-field examination in acyclovir ointment and (Roddy; Lukehart & Handsfield), 198
  transfusion (Risseeuw-Appel & Kothe), 200
  in United States in 1967–1979 (Fichtner & others), 77

T

Tetracycline, *N. gonorrhoeae* susceptibility to (Noble & Parekh), 18
Tetracycline resistance, of *M. hominis* (Christiansson & Mårdh), 240
  coexisting vaginal flora and (Koutsky & others), 374
Treponema pallidum, immobilizing antibody for (Kampmeier), 205
Trichomonas vaginalis, susceptibility of, to metronidazole (Ralph & others), 119

U

Ulceration, genital
  M. hominis in, in Africa (Piot & others), 285
  in Swaziland (Meheus & others), 33
Ureaplasma urealyticum
  in amniotic fluid at 16–20 weeks gestation, pregnancy outcome and (Cassell & others), 294
  minocycline-resistant, nongonococcal urethritis due to (Magalhães), 151
  monkey model for study of (Møller & Freundt), 359
  in nongonococcal urethritis and prostatitis (Oriel), 263
  in women with acute urethral syndrome (Stamm & others), 318
Urethra, discharge from, clinical diagnosis of (Rothenberg & Judson), 24
Urethral syndrome, acute, women with, *M. hominis* and *U. urealyticum* in (Stamm & others), 318
Urethritis
  gonococcal
    due to penicillinase-producing *N. gonorrhoeae*, cefoxitin in (Sanchez & others), 135
    due to fellatio, 41
  H. parainfluenzae in (Chowdhury & Pareek), 45
  nongonococcal
    genital mycoplasmas in (Oriel), 263
    minocycline-resistant *U. urealyticum* in (Magalhães), 151
Urinary tract, upper, *Mycoplasma hominis* in (Thomsen), 323

V

Vaginal flora, tetracycline resistance of *M. hominis* and (Koutsky & others), 374
Vaginitis, nonspecific, *M. hominis* in (Paavonen & others), 271
  in three clinic populations (Hill; Ruparelia & Embil), 114

W

White patients, *N. gonorrhoeae* auxotypes and (Noble & Parekh), 14
Women
  with acute urethral syndrome, *M. hominis* and *U. urealyticum* in (Stamm & others), 318
  as contacts of men with gonorrhea (Potterat & others), 29
  upper genital tract of, *M. hominis* in (Møller), 281

U.S. Postal Service
STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION
(Required by 39 U.S.C. 3685)

1A. TITLE OF PUBLICATION	1B. PUBLICATION NO.	2. DATE OF FILING
SEXUALLY TRANSMITTED DISEASES	3 7 1 3 5 0	Oct. 1, 1983
3. FREQUENCY OF ISSUE	3A. NO. OF ISSUES PUBLISHED ANNUALLY	3B. ANNUAL SUBSCRIPTION PRICE
Quarterly	4	$39.00

4. COMPLETE MAILING ADDRESS OF KNOWN OFFICE OF PUBLICATION (Street, City, County, State and ZIP Code) (Not printers): 2350 Virginia Avenue, Hagerstown, MD 21740

5. COMPLETE MAILING ADDRESS OF THE HEADQUARTERS OF GENERAL BUSINESS OFFICES OF THE PUBLISHER (Not printer): East Washington Square, Philadelphia, PA 19105

6. FULL NAMES AND COMPLETE MAILING ADDRESS OF PUBLISHER, EDITOR, AND MANAGING EDITOR (This item MUST NOT be blank)

PUBLISHER (Name and Complete Mailing Address): American Venereal Disease Association	East Washington Square Philadelphia, PA 19105
EDITOR (Name and Complete Mailing Address): William M. McCormack, M.D.	Downstate Medical Center 450 Clarkson Ave., Brooklyn, NY 11203
MANAGING EDITOR (Name and Complete Mailing Address): Deborah A. Finch	East Washington Square Philadelphia, PA 19105

7. OWNER (If owned by a corporation, its name and address must be stated and also immediately thereunder the names and addresses of stockholders owning or holding 1 percent or more of total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must be given. If owned by a partnership or other unincorporated firm, its name and address, as well as that of each individual must be given. If the publication is published by a nonprofit organization, its name and address must be stated.) (Item must be completed.)

FULL NAME	COMPLETE MAILING ADDRESS
American Venereal Disease Association	Box 22349 San Diego, CA 92122

8. KNOWN BONDHOLDERS, MORTGAGEES, AND OTHER SECURITY HOLDERS OWNING OR HOLDING 1 PERCENT OR MORE OF TOTAL AMOUNT OF BONDS, MORTGAGES OR OTHER SECURITIES (If there are none, so state):

FULL NAME	COMPLETE MAILING ADDRESS
None	

9. FOR COMPLETION BY NONPROFIT ORGANIZATIONS AUTHORIZED TO MAIL AT SPECIAL RATES (Section 422.12 only): The purpose, function, and nonprofit status of this organization and the exempt status for Federal income tax purposes (Check one)

(1) [X] HAS NOT CHANGED DURING PRECEDING 12 MONTHS (2) [ ] HAS CHANGED DURING PRECEDING 12 MONTHS (If changed, publisher must submit explanation of change with this statement.)

10. EXTENT AND NATURE OF CIRCULATION	AVERAGE NO. COPIES EACH ISSUE DURING PRECEDING 12 MONTHS	ACTUAL NO. COPIES OF SINGLE ISSUE PUBLISHED NEAREST TO FILING DATE
A. TOTAL NO. COPIES (Net Press Run)	3,080	3,030
B. PAID CIRCULATION 1. Sales through dealers and carriers, street vendors and counter sales	---	---
2. Mail Subscription	2,611	2,678
C. TOTAL PAID CIRCULATION (Sum of 10B1 and 10B2)	2,611	2,678
D. FREE DISTRIBUTION BY MAIL, CARRIER OR OTHER MEANS SAMPLES, COMPLIMENTARY, AND OTHER FREE COPIES	69	71
E. TOTAL DISTRIBUTION (Sum of C and D)	2,680	2,749
F. COPIES NOT DISTRIBUTED 1. Office use, left over, unaccounted, spoiled after printing	400	281
2. Return from News Agents	---	---
G. TOTAL (Sum of E, F1 and 2 - should equal net press run shown in A)	3,080	3,030

11. I certify that the statements made by me above are correct and complete. SIGNATURE AND TITLE OF EDITOR, PUBLISHER, BUSINESS MANAGER, OR OWNER: Joseph W. Lippincott, III, Circulation Manager

PS Form 3526 July 1982 (See instruction on reverse)